ML Telli

LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

C.H. Barrios, Nadia Harbeck, H.A. Zhang et al. · ESMO Open · 2023 · 22 citations · Full text

Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with <i>BRCA1</i> or <i>BRCA2</i> mutations and metastatic breast cancer: A randomized, phase 2 study

HS Han, V. Diéras, Markéta Palácová et al. · Cancer Research · 2017 · 20 citations

Tumor Biology, Metastatic Breast Cancer, Parp Inhibition +13

Abstract P6-20-01: METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)

A. Forero-Torres, Peter Schmid, Kim T. Blackwell et al. · Cancer Research · 2019 · 15 citations

Breast Oncology, Immunology, Pathology +20

Abstract P3-07-12: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis

ML Telli, A McMillan, JM Ford et al. · Cancer Research · 2016 · 13 citations

Homologous Recombination Deficiency, Breast Oncology, Pathology +19

Abstract PD3-13: Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer

Kevin Kalinsky, JJ Harding, Angela DeMichele et al. · Cancer Research · 2018 · 13 citations

Abstract Pd3-13, Breast Oncology, Medicine +14